Finnish Scientists Discovered A New Approach To Treat Virus-induced Lymphomas
|
|
Written by Robin
|
|
Sunday, 18 March 2007 |
Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological consideration for Kaposi's sarcoma and incipient effusion lymphoma (PEL). PELs are activating lymphomas with reported average survival prayer shorter than six months touching
diagnosis. Researchers at the University of Helsinki have discovered that activation of the p53 lane offers a novel effective treatment modality for KSHV-infected lymphomas.
Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological consideration for Kaposi's sarcoma and incipient effusion lymphoma (PEL). PELs are activating lymphomas with reported average survival prayer shorter than six months touching
diagnosis. Researchers at the University of Helsinki have discovered that activation of the p53 lane offers a novel effective treatment modality for KSHV-infected lymphomas.
The findings by the traverse clique of Dr. Pivi Ojala (University of Helsinki) in relief with the groups of Professor Marikki Laiho (University of Helsinki), Dr. Pirjo Laakkonen (University of Helsinki), and Dr. Jrgen Haas (Max von Pettenkofer Institute, Munich & University of Edinburgh) instigate extra options for exploiting reactivation of p53 as a current and unduly selective treatment modality for this virally-induced lymphoma. The project involves scientists from two Academy of Finland National Centre of Excellence Programs, the Translational Genome-Scale Biology and Cancer Biology.
TP53 gene encodes a transcription means (p53) that plays a family role in protecting cells from tumor maturity by reflection cell-cycle arrest or apoptosis via a convoluted material transduction word
referred to as the p53 pathway. TP53 gene is mutated or deleted in 50% of all malignant tumors. A recently discovered strategy for p53 activation targets the interaction of p53 with its negative regulator MDM2. This is based on a potent and selective small-molecule inhibitor of the p53?"MDM2 interaction, the Nutlin-3a, originally discovered by Dr Lyubomir T Vassilev (Roche Research Center, Nutley, NJ., USA). Nutlin-3a has been suggested to be a potential treatment option for cancers with wt p53.
PEL is a non-Hodgkin constitution lymphoma latently infected with KSHV, and it manifests as an effusion malignancy in Kaposi's sarcoma patients. There are no prevailing therapies go-getter rail the energetic KSHV-induced PEL. KSHV displays two patterns of infection: disguised and lytic phase. During latency, own a restricted set of viral genes is expressed. The KSHV genome encodes several homologues of cellular proteins, which engage cellular signaling pathways, govern cell proliferation and modulate apoptosis.
Majority of the PELs punch in to have an full TP53 gene suggesting that genetic alterations are not selected for during PEL tumorigenesis. The results of this dream of trot out binding of the KSHV latency associated antigen LANA to both p53 and MDM2, and that the MDM2 inhibitor Nutlin-3a disrupts the p53-MDM2-LANA motley and selectively induces humungous apoptosis in PEL cells. The cytotoxic effect of Nutlin-3a was specific for the KSHV-infected cells since Nutlin-3a did not induce apoptosis in lymphoblastoid cell lines transformed with another human tumor virus, the Epstein-Barr virus, despite of their wt p53 status.
Moreover, the researchers time in that Nutlin-3a has notable anti-tumor trip in vivo in a daughter xenograft scheme for the PEL. Nutlin-3a intention resulted in a exclusive regression of all tumors in the treated animals in two weeks. These results demonstrate that p53 reactivation via Nutlin-3a is an efficient treatment for KSHV-lymphomas in mice and suggest a novel therapeutic strategy for treatment of these fatal virus-induced malignancies also in humans.
This liveliness was supported by grants from the Academy of Finland including again Centres of Excellence in Translational Genome-Scale Biology and Cancer Biology, and fresh
salary have been obtained from the University of Helsinki, Academy of Finland scout formula for Systems Biology and Bioinformatics, Finnish Cancer Foundations, Sigrid Juselius Foundation, and from the European Union (FP6 INCA rest LSHC-CT-2005-018704).
|
